İbrahim CANER, Onur AKIN, Volkan HEPYANAR, Serdar Ümit SARICI, Ömer ERDEVE

Erken neonatal atelektazide kurtarıcı rhDNase tedavisi: Olgu sunumu

İnflamatuvar hücrelerin neden olduğu yıkım sonucu oluşan müküs tıkaçlarında yüksek oranda deoksi ribonükleik asit (DNA) bulunur. DNA bir polianyon molekül bileşiği olarak akciğer sekresyonlarının yoğunluk ve yapışkanlık özelliğinden sorumludur. Rekombinan insan DNase’ı (rhDNase) müküsteki ekstraselüler DNA’yı hidrolize ederek müküsü dakikalar içerisinde sulandırır ve onu yapışkan bir jelden akışkan sıvıya çevirir. Yenidoğanlarda, dirençli atelektazilerdeki sınırlı tedavi seçenekleri güvenli ve etkili yeni tedavi yöntemleri arayışına neden olmuştur. Bu yazıda doğumdan sonra 48. saatte solunum sıkıntısı nedeniyle hastaneye yatırılan, atelektazi tespit edilen ve non-invaziv bir yöntem olan nebül rhDNase ile kurtarıcı tedavisi yapılan bir olgu sunularak, yenidoğanda rhDNase kullanımının tartışılması amaçlanmıştır.

rhDNase rescue treatment in early neonatal atelectasis: Case report

Due to the lysis of inflammatory cells, there are large amounts of DNA present in the mucous plugs. DNA is a polyanion molecular compound that contributes to the increased viscosity and adhesiveness of lung secretions. Recombinant human DNase (rhDNase) liquefies the mucus within minutes by hydrolysing extracellular DNA in mucus and transforms it from a viscous gel to a flowing liquid. Limited therapeutic options in newborns with unresponsive atelectasis created the need for a new treatment which would be safe and effective. In this report; a newborn who was hospitalized for respiratory distress at 48th hour after birth and diagnosed as atelectasis, and treated by a non-invasive method which was nebulized rhDNAse is presented, and discussion of rhDNase treatment in newborns is aimed.

PDF

___

1. Nasr SZ, Strouse PJ, Soskolne E, et al. Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis. Chest 2001;120:203-8.
2. Merkus PJ, de Hoog M, van Gent R, et al. DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis. Eur Respir J 2001;18:734-7.
3. Fitzgerald DA, Hilton J, Jepson B, et al. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics 2005;116:e549-54.
4. El Hassan NO, Chess PR, Huysman MW, et al. Rescue use of DNase in critical lung atelectasis and mucus retention in premature neonates. Pediatrics 2001;108:468-70.
5. Kupeli S, Teksam O, Dogru D, et al. Use of recombinant human DNase in a premature infant with recurrent atelectasis. Pediatr Int 2003;45:584-6.
6. Kamin W, Klar-Hlawatsch B, Truebel H. Easy removal of a large mucus plug with a flexible paediatric bronchoscope after administration of rhDNase (Pulmozyme). Klin Padiatr 2006;218:88-91.
7. Erdeve O, Uras N, Atasay B, et al. Efficacy and safety of nebulized recombinant human DNase as rescue treatment for persistent atelectasis in newborns: case-series. Croat Med J 2007;48:139-44.
8. Hendriks T, de Hoog M, Lequin MH, et al. DNase and atelectasis in noncystic fibrosis pediatric patients. Crit Care 2005;9:R351-6.
9. Riethmueller J, Borth-Bruhns T, Kumpf M, et al. Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children. Pediatr Pulmonol 2006;41:61-6.
10. O’Donnell AE, Barker AF, Ilowite JS, et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998;113:1329-34.
11. Bryson HM, Sorkin EM. Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis. Drugs 1994;48:894- 906.